Brainstorm Cell Therapeutics (BCLI) Misses Q4 EPS by 3c
Brainstorm Cell Therapeutics (NASDAQ: BCLI) reported Q4 EPS of ($0.18), $0.03 worse than the analyst estimate of ($0.15).
For earnings history and earnings-related data on Brainstorm Cell Therapeutics (BCLI) click here.